We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

79 hedge funds and large institutions have $351M invested in Xenon Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

13% more funds holding

Funds holding: 70 → 79 (+9)

12% more capital invested

Capital invested by funds: $314M → $351M (+$36.6M)

0.68% more ownership

Funds ownership: 79.26% → 79.95% (+0.68%)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
79
Holders Change
+9
Holders Change %
+12.86%
% of All Funds
1.62%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
20
Increased
25
Reduced
10
Closed
11
Calls
$5K
Puts
–
Net Calls
+$5K
Net Calls Change
-$1K

Top Buyers

1
BI
BVF Inc
California
+$10.7M
2
O
OrbiMed
New York
+$10.6M
3
BBA
Baker Bros. Advisors
New York
+$10.2M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.78M
5
UBS AM
UBS AM
Illinois
+$4.64M

Top Sellers

1
CCM
Consonance Capital Management
New York
-$22.4M
2
ACM
Aquilo Capital Management
California
-$17M
3
VC
Vivo Capital
California
-$4.5M
4
BCM
Burrage Capital Management
Massachusetts
-$2.11M
5
IC
Ikarian Capital
Texas
-$1.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$44.1M +$10.7M +842,513 +32%
ACA
2
Avoro Capital Advisors
New York
$35.1M +$356K +28,000 +1%
O
3
OrbiMed
New York
$31.3M +$10.6M +835,105 +50%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$27.6M +$7.78M +611,518 +39%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$25.4M – – –
EAM
6
Eventide Asset Management
Massachusetts
$16M – – –
Capital International Investors
7
Capital International Investors
California
$13.2M – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$13M +$3.15M +247,200 +31%
NMC
9
NEA Management Company
Maryland
$12.4M – – –
Capital World Investors
10
Capital World Investors
California
$12.1M – – –
BBA
11
Baker Bros. Advisors
New York
$10M +$10.2M +799,102 New
Bank of New York Mellon
12
Bank of New York Mellon
New York
$9.97M +$1.51M +118,813 +18%
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$8.27M +$946K +74,351 +13%
BC
14
Boxer Capital
California
$7.52M – – –
PHP
15
Parkman Healthcare Partners
Connecticut
$7.4M – – –
ACP
16
Acuta Capital Partners
California
$6.49M -$1.41M -111,000 -18%
RSCM
17
Rock Springs Capital Management
Maryland
$6.47M +$200K +15,711 +3%
DCM
18
Driehaus Capital Management
Illinois
$5.82M +$24.2K +1,901 +0.4%
Citadel Advisors
19
Citadel Advisors
Florida
$4.89M -$1.47M -115,769 -23%
UBS AM
20
UBS AM
Illinois
$4.57M +$4.64M +364,757 New
DCM
21
DAFNA Capital Management
California
$4.35M – – –
GTC
22
Ghost Tree Capital
New York
$4.08M – – –
IC
23
Ikarian Capital
Texas
$3.74M -$1.85M -145,409 -33%
SCM
24
Soleus Capital Management
Connecticut
$3.15M +$3.02M +237,669 +1,797%
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$2.63M +$854K +67,110 +47%
1
2 3 4

XENE Hedge Fund Activity: Q2 2020 in Review

79 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2020, worth a combined $351M — up 12% from $314M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new XENE positions and 11 closed out — a net gain of 9 holders — while 25 added to existing stakes and 10 trimmed.

The largest buyer was BVF Inc, adding an estimated $10.7M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $22.4M sold.

  • 79 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2020, up from 70 in Q1 2020.
  • Funds reported $351M of Xenon Pharmaceuticals stock for Q2 2020, up 12% quarter-over-quarter.
  • 20 funds opened new Xenon Pharmaceuticals positions in Q2 2020 and 11 closed out, a net change of +9 holders.
  • The largest Xenon Pharmaceuticals buyer in Q2 2020 was BVF Inc, an estimated $10.7M added.
  • The largest Xenon Pharmaceuticals seller in Q2 2020 was Consonance Capital Management, an estimated $22.4M sold.

Based on aggregated 13F filings for Q2 2020.